Moderna went public with news in February that federal vaccine regulators had called its clinical trials inadequate and rejected their application for review of the new shot.
Vaccine manufacturer Moderna said Wednesday the US Food and Drug Administration (FDA) had approved its new influenza vaccine, nearly six months after the regulator briefly rejected an application for review.
The company's first mRNA-based flu vaccine, mFLUSIVA, has been approved for use in all adults age 50 and older, the US-based pharmaceutical firm said in a release.
"Moderna expects to have mFLUVISA available for eligible populations in the US for the 2026-2027 respiratory virus season," the release said.
Moderna went public with news in February that federal vaccine regulators had called its clinical trials inadequate and rejected their application for review of the new shot.
